IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies

INconnect28 - 29 September 2017, Berlin, Germany.
Due to evolving technology and accelerated growth in research and development activities, cloud computing and IT business technology have increased rapidly. Over the past decades, cloud computing has had profound impact in Life Sciences industry by bringing efficiencies, allowing enterprise-wide agility, and boosting patient outcomes. Cloud computing solutions has reshaped promotional strategies of various Life Science companies and transformed modes of interactions with physicians.

As Life Science sector is currently improving and accelerating its correlation with IT, the Life Sciences Cloud Coalition have moved to the cloud computing and working with their patient through it.

Global Cloud Computing in Life Science Market is expected to expand at a rapid pace during the period of 2015 - 2023 due to the increasing use of cloud computing in Life Science research and development.

This event will serve as a business networking platform as well as a scientific examination of the advantages and disadvantages in implementing IT modernization and cloud computing.

Key Topics

  • Examination of the EU General Data Protection Regulation and practical implementation
  • Analysis of Data security and Privacy Global Outlook
  • Benchmark your IT approach to transformation
  • Understanding the need for Scalability and Flexibility of Cloud Computing
  • IT Infrastructure Modernisation in Pharma and Rea
  • World Implementations
  • Factors driving Digital and Mobile Technologies in Patient Engagement
  • Cloudy 2020: Cloudy Opportunities and Challenges in the future
  • Harmonization of data privacy laws across Europe
  • Discussion of pros and cons of private cloud and public cloud
  • e-commerce trends and application in Cloud

Target Audience

  • Pharmaceutical companies
  • Cloud Content Solution/Software Providers
  • Biotechnology companies
  • Medical Technology companies
  • Research Centers
  • Physicians

For further information, please visit:
http://www.inconnect.net/events/events/it-transformation-and-cloud-content-management-for-medtech-biotechnology-and-pharmaceutical-companies

About INconnect
Academic management research shows that knowledge is a crucial asset for companies concerning sustained competitive advantage. Markets provide opportunities for companies to succeed in organizing themselves around new information on industry trends and technology. Those are the companies that can and will innovate.

Improved technologies and strategies are required for innovation. The only possible fuel for innovation are ideas. Ideas arise when the right people, get the right information, in the right context.

INconnect uses its extensive international network in top-executive event management to bring together industry leaders, lawmakers and experts.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...